CD133 MicroBead Kit, human

Name: CD133 MicroBead Kit, human
Availability: InStock

CD133 MicroBead Kit, human

Product overview

The CD133 MicroBead Kit allows basic isolation or depletion of CD133

⁺

cells from various sources.

Note:

Optimized isolation kits with improved performance are available for the following tissues:

For hematopoietic or endothelial progenitor cells, choose the CD133 MicroBead Kit – Hematopoietic Tissue
For cancer or tissue stem cells the CD133 MicroBead Kit – Tumor Tissue is recommended

Product data and images for CD133 MicroBead Kit, human

Figures

Figure 1

Isolation of CD133

⁺

cells from human PBMCs using the CD133 MicroBead Kit, two MS Columns, and a MiniMACS™ Separator.

PBMCs before separation	Isolated CD133 ⁺ cells
View details Figure 1 Isolation of CD133 ⁺ cells from human PBMCs using the CD133 MicroBead Kit, two MS Columns, and a MiniMACS™ Separator.	View details Figure 1 Isolation of CD133 ⁺ cells from human PBMCs using the CD133 MicroBead Kit, two MS Columns, and a MiniMACS™ Separator.

Specifications for CD133 MicroBead Kit, human

Overview

The CD133 MicroBead Kit allows basic isolation or depletion of CD133

⁺

cells from various sources.

Note:

Optimized isolation kits with improved performance are available for the following tissues:

For hematopoietic or endothelial progenitor cells, choose the CD133 MicroBead Kit – Hematopoietic Tissue
For cancer or tissue stem cells the CD133 MicroBead Kit – Tumor Tissue is recommended

Detailed product information

Background information

CD133, formerly known as AC133, recognizes epitope 1 of the CD133 antigen.

^2,3

It is a marker that is frequently found on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells. In the hematopoietic system, CD133 is expressed on a small portion of CD34

^–

cells

⁴

as well as on a subset of CD34

^bright

stem and progenitor cells in human fetal liver, bone marrow, cord blood, and peripheral blood

⁵

. CD133 has also been found to be expressed on circulating endothelial progenitor cells,

^6,7

fetal neural stem cells,

^8,9

other tissue-specific stem cells, such as renal

¹⁰

, prostate

¹¹

, and corneal

¹²

stem cells, cancer stem cells from tumor tissues, as well as ES and iPS cell-derived cells.

There is a growing interest in CD133-expressing stem cells from normal blood or bone marrow in regenerative medicine, for example, in the field of cardiovascular

^13-17

, liver, or peripheral artery diseases

^18-20

.

The CD133 MicroBeads included in the kit recognize epitope CD133/1. For quality control staining of isolated CD133

⁺

cells, the use of CD133/2 (293C3)-PE or -APC is recommended.

Columns

For positive selection: MS, LS, XS, or autoMACS

^®

Columns. For depletion: LD, D, or autoMACS Columns.

Resources for CD133 MicroBead Kit, human

Documents and Protocols

Brochures/posters

Neuroscience - Inspiring technologies for creative scientists

Brochures/posters

Cancer Research - Understanding cancer begins with the cell

App notes/customer reports

Intracellular labeling of multiple cell types for MRI-based in vivo cell tracking. Kernbach et al. (2012) MACS&more 14(2).

App notes/customer reports

Array-based analysis of microRNA and mRNA expression characterizes early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells. Bissels et al. (2012) MACS&more 14(2).

References for CD133 MicroBead Kit, human

Publications

Galic, Z. et al. (2006) T lineage differentiation from human embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 103: 11742-11747
Yin, A. H. et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012
Piechaczek, C. (2001) CD133. J. Biol. Regul. Homeost. Agents 15: 101-102
Gallacher, L. et al. (2000)
Isolation and characterization of human CD34
^–
Lin
^–
and CD34
⁺
Lin
^–
hematopoietic stem cells using cell surface markers AC133 and CD7.
Blood 95(ARVO Annual Meeting Abstract): 2813-2820
Bühring, H. J. et al. (1999) Expression of novel surface antigens on early hematopoietic cells. Ann. N. Y. Acad. Sci. 872: 25-39
Gehling, U. M. et al. (2000)
In vitro
differentiation of endothelial cells from AC133-positive progenitor cells.
Blood 95: 3106-3112
Peichev, M. et al. (2000)
Expression of VEGFR-2 and AC133 by circulating human CD34
⁺
cells identifies a population of functional endothelial precursors.
Blood 95: 952-958
Uchida, N. et al. (2000) Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. U.S.A. 97: 14720-14725
Cummings, B. J. et al. (2005) Human neural stem cells differentiate and promote locometer recovery in spinal cord-injured mice. Proc. Natl. Acad. Sci. U.S.A. 102: 14069-14074
Bussolati, B. et al. (2005) Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166: 545-555
Richardson, G. et al. (2004) CD133, a novel marker for human prostatic epithelial stem cells. J. Cell. Sci. 117: 3539-3545
Thill, M. et al. (2004)
Identification of a population of CD133
⁺
precursor cells in the stroma of human cornea.
Invest. Ophthalmol. Vis. Sci. 45: 3519
Stamm, C. et al. (2003) Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361(9351): 45-46
Stamm, C. et al. (2007)
Intramyocardial delivery of CD133
⁺
bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies.
J. Thorac. Cardiovasc. Surg. 133: 717-725
Klein (2007) Eur. Cardiovasc. Dis. 1: 123-125
Klein, H. M. et al. (2007)
Intramyocardial implantation of CD133
⁺
stem cells improved cardiac function without bypass surgery.
Heart Surg. Forum 10: E66-69
Bartunek et al. (2005) Circulation 30: 178-183
am Esch, J. S. 2nd et al. (2005)
Portal application of autologous CD133
⁺
bone marrow cells to the liver: a novel concept to support hepatic regeneration.
Stem Cells 23(4): 463-470
Fürst, G. et al. (2007)
Portal vein embolization and autologous CD133
⁺
bone marrow stem cells for liver regeneration: initial experience.
J. Immunother. 243(1): 171-179
Cañizo et al. (2007)
Peripheral endothelial progenitor cells (CD133
⁺
) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up.
Cytotherapy 9(1): 99-102

Data and images